Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QPD101
- Development stage
- Preclinical
- Lead developer
- RestoriT
01
Overview
QPD101 is an investigational therapeutic candidate being developed by RestoriT, a biotechnology company focused on andrology and supportive care. As of early 2025, the asset is part of RestoriT's internal pipeline, specifically targeting applications within the field of men's health and supportive treatments. While the company has identified QPD101 for these indications, specific details regarding its molecular target, pharmacological modality (e.g., small molecule vs. biologic), and exact mechanism of action have not been publicly disclosed. The drug is currently in the early stages of development, aimed at addressing unmet needs in male reproductive health and related supportive care settings.
Beyond the preview
Go deeper on QPD101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QPD101.